About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The company leverages receptor-associated proteins (RAPs) via its proprietary RAP technology platform to precisely target disease-driving neurocircuits, enabling more selective CNS drugs than conventional approaches. Its lead program, RAP-219, is being developed for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania, with additional discovery-stage programs in chronic pain and hearing disorders.
Company details
Funding
Total raised
$250M
Last stage
Public
Investors
Founders
David Bredt
Pioneered the discovery of receptor-associated proteins (RAPs) and their targeting by small molecules; his foundational research underpins Rapport's entire RAP technology platform.
Abraham N. Ceesay
Brings nearly two decades of biopharma experience; previously President of Cerevel Therapeutics and CEO of Tiburio Therapeutics.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.